Menlo Ventures

Today, I am excited to announce that FireHydrant has acquired Blameless 🔥 Since 2018, FireHydrant and Blameless have been tackling the enormous incident management category in our own unique ways. However, during these past six years, we've held an unifying belief: businesses of all sizes will inevitably adopt modern incident management tooling. So why not simply embrace that belief together as one? Recent shifts in the market have only solidified my confidence that the time to tackle the enterprise portion of this market has arrived. Teams are demanding more from their on-call and alerting tools, and robust incident management practices are commonplace from early adopters to Fortune 500s. This acquisition empowers us to extend our lead as the preferred enterprise incident management platform and solve the unique challenges that building reliable software presents. The FireHydrant and Blameless teams have collaborated for months to make this process as smooth as possible focusing on the best of both platforms that we can bring to our customers. In addition, I'm excited that Accel and Third Point Ventures have joined us on our mission for a more reliable web. They both share the strong conviction that we have for incident management and have already proven to be great partners. Vas Natarajan and Dan Moskowitz will both take FireHydrant board seats. For the next several years, we'll continue setting the standard for incident management. We are now in a unique position to realize our vision: A world where all software is reliable. Read it in TechCrunch: https://lnkd.in/eas5Uafk

It's that time of year again! Time for a deep-dive into biotech venture capital. STAT published its annual "Ranking Biotech's Top Venture Capital Firms" report this week, where we gather and analyze data on just how well these financial firms are doing multiplying limited partners' money. We've also got inside details on what firms like Flagship Pioneering, Khosla Ventures, Sofinnova Investments , OrbiMed, Third Rock Ventures, Atlas Venture, and many, many others have been up to over the last year. Which firm do you think is the best biotech investor?

I’m excited to announce that Eppo raised $28M in series B financing! The round was led by Davis Treybig at Innovation Endeavors, with participation from Preeti Rathi from Icon Ventures. It comes after a huge year for Eppo where we more than tripled revenue and are now working with experimentation teams at Coinbase, DraftKings Inc., and Perplexity. The experimentation industry has blossomed in the past two years, due to two topics on the mind of every board room today: 1. How do we somehow grow faster while having to cut costs? What options do I have for efficient growth? 2. How do we become fluent in AI before an AI-native competitor rises up? The answer to both is experimentation, and specifically making experiments pervasive, fast, and trustworthy. When teams operate with a “test-first” mindset, bad investments are killed quickly, good investments are reinforced, and innovative staff are empowered. We’ve seen the market realize that a new type of experimentation platform is now on the market, one that reflects the horsepower and flexibility of the systems that drive the FAANGs. Where legacy vendors could only test simple UX changes on marketing websites, Eppo customers are implementing personalization, de-risking product launches, ensembling AI models, and designing omni-channel integrated campaigns. Core to this difference is that legacy vendors could only track clicks, never core business KPIs like margin, cost, quality, subscriptions. In short, most company experimentation programs have grown stunted, bottlenecked by manual work and scarce expert resources. This leads to sluggish operations that don’t drive growth, and teams that get used to wondering what their tool can measure. Eppo was built for teams that are asking, “what do we NEED to measure for growth”, and how does the operating cost to measure these needs go to zero. We’re hiring! Check out our careers page for roles in marketing, PM, engineering, and sales DM me or sign up for a demo if you’d like to talk experimentation. Whether scaling 1000s of experiments across a global 500 company or running your first test, we’ve seen it all at this point! We’d love to chat. https://lnkd.in/dr7UZXka